AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02273115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter
Study NCT02605694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
Study NCT02605694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
Study NCT02605694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)
Study NCT02725177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)
Study NCT02725177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection -Treatment Extension
Description: 24 open label extension permitted in subjects who respond to treatment
Study NCT03044665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
Study NCT03044665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus ezetimibe
Description: Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
Study NCT00385086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF blocker
Description: Treatment with TNF-alpha blocker
Study NCT00385086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo
Study NCT04741243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock wave
Description: Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
Study NCT01972425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker-based diagnostic
Description: The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
Study NCT01296386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC84
Description: IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
Study NCT01948310 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
Study NCT03057873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein, high fiber dietary supplement
Description: Dry powder to be mixed with 10 ounces of cold water
Study NCT03057873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder to be mixed with 10 ounces of cold water
Study NCT02355093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block (ACB)
Description: We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
Study NCT02355093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block (FNB)
Description: the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
Study NCT02355093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study NCT02355093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Study NCT04630015 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Participants will complete study specific survey
Study NCT02605694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
Study NCT01333618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: curving introducer Günther Tulip Filter
Description: The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
Study NCT01333618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: straight introducer Günther Tulip Filter
Description: The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
Study NCT02524080 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triage to optimal healthcare level
Description: Triage to optimal healthcare level
Study NCT01070355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid free fatty acid
Description: An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
Study NCT01070355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken twice daily for 2-6 weeks before liver resection.
Study NCT04652024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: , patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Administered orally
Study NCT03098407 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered subcutaneously (SC)
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW)
Description: Administered SC
Study NCT02072096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Description: Administered SC
Study NCT01591564 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy for youth with SMD (IPT-SMD)
Description: Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
Study NCT03774537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of hUC-MSCs
Description: Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
Study NCT03774537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No transplantation of hUC-MSCs
Description: Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
Study NCT02799992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 689 nm Laser Treatment of the Macula
Study NCT02799992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Half Dose Photodynamic Therapy
Study NCT00841022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information with comics
Description: Information of children with comic leaflet
Study NCT04220606 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
Study NCT01177657 — intervention group
Intervention type: PROCEDURE
Intervention: Stool sampling
Description: Stool samples collected and checked for the presence of rotavirus
Study NCT01325909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise programme
Study NCT03098407 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
Study NCT03626974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Venipuncture for blood collection
Study NCT03626974 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Venipuncture
Description: Venipuncture for blood collection
Study NCT03626974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuser spreading odor
Description: Diffuser will place under a Hood with an air-flow
Study NCT03626974 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Diffuser spreading odor
Description: Diffuser will place under a Hood with an air-flow
Study NCT01556633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu (oseltamivir)
Description: Single dose of Tamiflu in volunteers on dialysis
Study NCT01556633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu (oseltamivir)
Description: Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
Study NCT02905773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: root canal therapy
Description: effect of devices ( ProTaper and Reciprocal Files)
Study NCT02905773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: root canal retreatment
Description: effect of devices ( ProTaper and Reciprocal Files)
Study NCT01171521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaClose Group
Description: The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
Study NCT03667131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate
Description: Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
Study NCT03667131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 5 mg tablet, every 12 hrs for 90 days.
Study NCT04627350 — intervention group
Intervention type: OTHER
Intervention: Response to pulmonary finding (nodule, mass)
Description: Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
Study NCT02097199 — intervention group
Intervention type: OTHER
Intervention: Increased sports workload
Description: At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study.
Study NCT01729832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast reconstruction
Description: Undergo DIEP flap breast reconstruction using the StealthStation navigation system
Study NCT01729832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative imaging
Description: Undergo DIEP flap breast reconstruction using the StealthStation navigation system
Study NCT00804440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg
Study NCT00120250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
Study NCT00120250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eszopiclone
Description: The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
Study NCT04443777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
Study NCT04443777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
Study NCT04772924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fasting
Description: more than 12 hour of fasting as ceremony of Ramadan
Study NCT04772924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: not fasting
Description: preferred not to take long term fasting
Study NCT01525511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets
Study NCT01525511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets
Study NCT00177346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAS with cerebral protection
Study NCT00177346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAS without cerebral protection
Study NCT01850381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM608
Description: For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Study NCT01850381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
Study NCT00585585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: oral, 50-300 mg, daily
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Study NCT02857465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Study NCT01415440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
Study NCT01415440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosing will parallel that of Lisdexamfetamine.